Cogent Biosciences, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$333.4M | -$275.9M | -$208.1M | -$147.8M | -$75.6M |
| Cash from operations | -$264.4M | -$207.8M | -$153.6M | -$118.6M | -$58.8M |
| Capital expenditure | $1.6M | $573,000 | $2.8M | $6.9M | $1.7M |
| Free cash flow | -$266.0M | -$208.4M | -$156.4M | -$125.5M | -$60.5M |
| Impairments | — | — | — | — | $0 |
| Total assets | $937.6M | $327.9M | $313.4M | $300.8M | $232.1M |
| Total liabilities | $301.2M | $71.6M | $55.6M | $45.1M | $17.9M |
| Total debt | $230.0M | — | — | — | — |
Shares outstanding 170.9M · Free float 91.8%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.